摘要
目的观察反应停联合E-CHOP方案治疗难治性复发型非霍奇金淋巴瘤(NHL)的临床疗效。方法将46例难治性复发型NHL患者均分为两组,对照组采用E-CHOP方案治疗,治疗组采用反应停联合E-CHOP方案治疗,以21d为1个周期,对完成4个周期以上者进行疗效评价及随访其1年生存率和2年生存率。结果治疗组23例中完全缓解(CR)11例,部分缓解(PR)6例,无变化(ND)4例,进展(PD)2例,总有效率为73.91%;对照组23例中CR6例,PR3例,ND8例,PD6例,总有效率为39.13%,两组比较有显著性差异。治疗组1年生存率和2年生存率分别为86.96%(20/23)和56.52%(13/23),对照组1年生存率和2年生存率分别为78.26%(18/23)和39.13%(9/23),较之对照组,治疗组1年生存率有增加趋势,但统计学比较无差异,而2年生存率两组比较有统计学差异(P<0.05)。结论反应停联合E-CHOP方案治疗难治性复发型NHL疗效满意,值得临床推广。
Objective To evaluate the therapeutic effects and adverse reactions of combined thalidomide and E-CHOP in the treatment of advanced non- Hodgkin＇s lymphoma （NHL）. Methods 23 patients with advanced NHL received thalidomide and chemotherapy of E- CHOP,three weeks as one circle. The efficacy was evaluated after 4 circles. Results There were CR（11）, PR（6）, ND（4）, PD（2）. The overall efficacy rate was 73.91%. There was no difference in the one year survival rate of two groups. But there was significant difference in the two-year survival rate. Conclusion combined thalidomide with E- CHOP can gain the good therapeutic effect in advanced NHL. The side reactions can be well tolerated.
出处
《中国药业》
CAS
2008年第21期53-55,共3页
China Pharmaceuticals
